Julian Symons
Chief Tech/Sci/R&D Officer chez ALIGOS THERAPEUTICS, INC.
Fortune : 386 183 $ au 31/03/2024
Profil
Julian A.
Symons is currently the Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. Prior to this, he worked as the Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Dr. Symons holds a doctorate degree from York University and an undergraduate degree from the University of Central Lancashire.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 394 064 ( 0,54% ) | 386 183 $ | 31/03/2024 |
Postes actifs de Julian Symons
| Sociétés | Poste | Début |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Anciens postes connus de Julian Symons
| Sociétés | Poste | Fin |
|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/04/2018 |
Formation de Julian Symons
| York University | Doctorate Degree |
| University of Central Lancashire | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
